智通财经APP获悉，复宏汉霖(02696)再涨超9%，截至发稿，涨8.54%，报36.85港元，成交额3528.23万港元。
消息面上，复星医药公布，今年4月11日至17日期间，控股子公司复星医药产业与上海善梧、无锡通善、舟山果运及Henlink分别签订转让协议，控股子公司复星医药产业拟以24.60港元/股的价格受让上海善梧、无锡通善、舟山果运及Henlink合计持有的2103万股复宏汉霖非上市股份，转让价款共计5.17亿港元。在此次增持之后，复星医药持有复宏汉霖的股权比例将增至63.43%。
值得注意的是，在4月15日举办的复宏汉霖全球研发日上，复宏汉霖密集披露了HLX22（抗HER2单抗）、HLX43（PD-L1 ADC）等核心管线的突破性进展。此外，公司宣布国际化2.0战略聚焦日本市场，计划2026年前在15国同步上市创新药，并建立48000升全球化产能支撑常态化供货。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.